Compare Garmin Ltd. (GRMN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Travere Therapeutics Inc. Common Stock — how do they compare? Garmin Ltd. trades at $281.37 (market cap $53.31B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Garmin Ltd. is far larger — about 10.9× Travere Therapeutics Inc. Common Stock's market cap, and Garmin Ltd. pays a 1.52% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 84 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GRMN | TVTX | |
|---|---|---|
Market Cap | $53.31B | $4.88B |
Volume | 778,898 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $313.16 | $67.52 |
52-Week Low | $187.10 | $26.79 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $50.82B | $5.01B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $279.72, up 4.86% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains robust fundamentals with 24.47% net margins and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive news includes product awards and institutional accumulation, though technical indicators suggest near-term resistance.
GRMN presents a mixed outlook: strong profitability and analyst consensus target of $320.25 offer 14.5% upside, but bearish technicals and high valuation ratios (P/E 28.53) pose risks. Investment appeal hinges on execution of 2026 revenue guidance ($7.7B) amid competitive pressures in consumer electronics.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
